HD Biosciences, a contract drug research services provider backed by Pfizer and Eli Lilly, has been acquired by WuXi AppTec for an undisclosed sum.
Healthcare group WuXi AppTec has acquired China-based pharmaceutical research services provider HD Biosciences for an undisclosed amount, giving exits to pharmaceutical firms Pfizer and Eli Lilly.
Founded in 2002, HD supplies preclinical contract research services to drug developers, including target validation, hit identification, lead discovery, in vivo pharmacology and screening. It will continue to operate post-acquisition as a subsidiary of WuXi AppTec.
The company raised an undisclosed sum in a 2008 series A round co-led by Eli Lily subsidiary Lilly…
